| 1.8 -0.04 (-2.17%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.33 | 1-year : | 2.61 |
| Resists | First : | 1.99 | Second : | 2.24 |
| Pivot price | 1.86  |
|||
| Supports | First : | 1.61 | Second : | 1.33 |
| MAs | MA(5) : | 1.92 |
MA(20) : | 1.81 |
| MA(100) : | 1.92 |
MA(250) : | 2.3 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 48.7 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 5.44 | Low : | 1.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PROK ] has closed above bottom band by 34.2%. Bollinger Bands are 14.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.82 - 1.84 | 1.84 - 1.85 |
| Low: | 1.72 - 1.73 | 1.73 - 1.75 |
| Close: | 1.78 - 1.8 | 1.8 - 1.82 |
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Thu, 09 Jul 2026
ProKidney (NASDAQ:PROK): Can This Penny Stock Rebound? - Kalkine Media
Thu, 09 Jul 2026
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite? - Kalkine Media
Mon, 06 Jul 2026
ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike - Stock Titan
Fri, 03 Jul 2026
PROK - ProKidney Corp Short Interest - Finviz
Mon, 29 Jun 2026
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Index - marketscreener.com
Sat, 27 Jun 2026
Price to earnings forward of ProKidney Corp. – NASDAQ:PROK - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 205 (M) |
| Held by Insiders | 1.5676e+008 (%) |
| Held by Institutions | 47.7 (%) |
| Shares Short | 19,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6192e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -19 % |
| Return on Assets (ttm) | 881.8 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 889000 % |
| Gross Profit (p.s.) | -1 |
| Sales Per Share | -29.05 |
| EBITDA (p.s.) | 522941 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | -0.43 |
| Dividend | 0 |
| Forward Dividend | 1.755e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|